Trial Profile

CLARITY: Assessment of VenetoCLAx (ABT-199) in combination with IbRutInib in relapsed/refracTory Chronic LymphocYtic Leukaemia

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 19 May 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ibrutinib (Primary) ; Venetoclax (Primary)
Indications Chronic lymphocytic leukaemia
Focus Therapeutic Use
Acronyms CLARITY

Most Recent Events

13 Dec 2022 Results of exploratory analysis of this study presented at the 64th American Society of Hematology Annual Meeting and Exposition
04 Apr 2022 Status changed from active, no longer recruiting to completed.
14 Dec 2021 Planned End Date changed from 1 Dec 2021 to 1 Apr 2022.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com